Phase 4 N=36 Randomized Single-blind Treatment

Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease

Graves Disease · Hyperthyroidism

Bottom Line

View on ClinicalTrials.gov: NCT00946296 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2015

Primary outcome: Primary: Blood Loss During Surgery — 61.67; 161.67 mL

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Potassium Iodide (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Massachusetts, Worcester
Primary completion: Apr 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Blood Loss During Surgery	61.67; 161.67	—

Summary

The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as definitive management of their Graves Disease.

Eligibility Criteria

Inclusion Criteria

Adult patients with a clinical diagnosis of Graves Disease
Patients who have selected surgical resection as treatment of their Graves Disease
Prior use of anti thyroid medication so that patient is clinically and biochemically euthyroid

Exclusion Criteria

Patients deemed unfit for surgery by operating surgeon or anesthesist
Patients who are clinically hyperthyroid or have T3 or T4 levels 2X the upper limit of normal

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00946296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.